Grufity logoGrufity logo

IDXX

415.39USD-6.91(-1.64%)Market Closed

IDEXX Laboratories Inc

Market Summary

USD415.39-6.91Market Closed
-1.64%

IDXX Alerts

IDXX Stock Price

RSI Chart

Valuation

Market Cap

30.3B

Price/Earnings

45.68

Price/Sales

9.17

Price/Cashflow

52.49

MarketCap/EBT

36.83

Price/Sales

Profitability

Operating Margin

58.63%

EBT Margin

24.89%

Return on Equity

145.28%

Return on Assets

25.47%

Fundamentals

Revenue

Revenue (TTM)

3.3B

Revenue Y/Y

3.85%

Revenue Q/Q

-2.19%

Earnings

Earnings (TTM)

669.7M

Earnings Y/Y

3.25%

Earnings Q/Q

37.1%

Price Action

52 Week Range

317.06664.70
(Low)(High)

Last 7 days

1.6%

Last 30 days

11.7%

Last 90 days

17.1%

Trailing 12 Months

-29.9%

Financial Health

Current Ratio

0.89

Investor Care

Buy Backs (1Y)

2.33%

Diluted EPS (TTM)

7.87

Peers (Alternatives to IDEXX Laboratories)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.3B
31.3B
7.44% -13.32%
27.1
5.87
11.35% 14.95%
174.5B
45.0B
5.90% -20.28%
20.4
3.83
6.43% 8.90%
115.4B
30.8B
-8.94% -28.67%
22.17
3.71
-3.11% -8.14%
30.3B
3.3B
11.73% -29.86%
45.68
9.17
6.53% -11.52%
16.7B
2.9B
9.09% -44.50%
26.46
5.74
8.50% 2.96%
MID-CAP
6.4B
806.4M
33.31% -13.25%
-331.15
7.96
20.10% -221.96%
5.2B
664.2M
-8.45% 108.34%
160.13
7.81
76.53% 218.01%
3.7B
2.3B
1.52% -34.01%
3.27
1.42
24.87% 6.11%
SMALL-CAP
1.4B
527.2M
13.08% -61.78%
29.31
2.69
12.53% -20.65%
1.4B
233.4M
-1.44% -72.82%
-4.82
6.12
8.78% -318.40%
1.4B
333.0M
-0.94% 62.20%
32.26
4.08
4.76% -40.54%
765.9M
259.0M
1.67% -60.18%
-43.31
2.97
3.62% -967.02%
44.3M
7.9M
-4.15% -78.74%
-1.23
5.93
23.02% -7.81%
17.5M
37.6M
-65.18% -99.22%
-0.13
0.46
1.85% -22.51%

Financials for IDEXX Laboratories

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue0.9%3,3403,3093,2743,2153,135
Cost Of Revenue-0.2%1,3641,3661,3571,3261,308
Gross Profit1.7%1,9761,9421,9171,8891,843
  S&GA Expenses1.1%521515504487474
  R&D Expenses3.0%257249164161154
Earnings Before Taxes1.8%839823904903888
Net Income0.9%670664735745757
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets1.3%2,6402,6072,5932,4372,386
  Current Assets1.5%1,0591,0431,090956938
    Cash Equivalents-13.3%99114205144145
  Inventory6.7%355333302269258
  Net PPE3.1%612594593588573
  Goodwill-0.1%355356361359355
Liabilities0.6%2,1642,1501,9531,7471,630
  Current Liabilities2.0%1,1901,167971764634
    LT Debt, CurrentNaN%---7575
    LT Debt, Non Current-0.9%761768773775778
Shareholder's Equity4.2%476457640690755
  Retained Earnings5.6%3,4273,2463,1142,9202,758
  Additional Paid-In Capital1.4%1,4201,4001,3771,359-
Shares Outstanding-0.5%8383848585
Minority Interest-100.0%-1---
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations0.3%580578746756765
  Share Based Compensation8.0%4643403836
Cashflow From Investing0.3%-190.16-190.64-310.22-292.97-264.62
Cashflow From Financing14.8%-420.04-492.93-581.24-697.41-531.20
  Buy Backs-0.9%990999881747502

Risks

What is the probability of a big loss on IDXX?

55.8%


Probability that IDEXX Laboratories stock will be more than 20% underwater in next one year

31.5%


Probability that IDEXX Laboratories stock will be more than 30% underwater in next one year.

12.3%


Probability that IDEXX Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IDXX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if IDEXX Laboratories was unfortunately bought at previous high price.

Returns

Cumulative Returns on IDXX

24.4%


10-Year Cumulative Returns

29.1%


7-Year Cumulative Returns

21.1%


5-Year Cumulative Returns

18.2%


3-Year Cumulative Returns

What are the long-term rolling returns for IDXX?

FIve years rolling returns for IDEXX Laboratories.

Which funds bought or sold IDXX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
ADDED
8.33
5,000
818,000
0.03%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
9,698,000
9,698,000
0.11%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
ADDED
6,300
25,313,000
25,696,000
0.95%
2022-11-22
IHT Wealth Management, LLC
NEW
-
215,000
215,000
0.02%
2022-11-22
CVA Family Office, LLC
ADDED
168.75
42,000
70,000
0.02%
2022-11-22
B. Riley Wealth Advisors, Inc.
REDUCED
-22.02
-183,000
482,000
0.01%
2022-11-21
17 CAPITAL PARTNERS, LLC
UNCHANGED
-
-21,000
276,000
0.38%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.23
-4,041,000
44,916,000
0.08%
2022-11-21
FourThought Financial, LLC
ADDED
10.28
2,000
115,000
0.02%
2022-11-21
DEARBORN PARTNERS LLC
ADDED
3.9
-14,000
399,000
0.02%

1–10 of 48

Latest Funds Activity

Are funds buying IDXX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own IDXX

IDEXX Laboratories News

MarketBeat

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director M Anne Szostak Sells 740 Shares.3 hours ago

GuruFocus.com

Morningstar.ca

IDXX Fair Value

Recent SEC filings of IDEXX Laboratories

View All Filings
Date Filed Form Type Document
Nov 16, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 09, 2022
4
Insider Trading
Nov 01, 2022
8-K
Current Report
Nov 01, 2022
4
Insider Trading
Nov 01, 2022
10-Q
Quarterly Report
Oct 21, 2022
8-K
Current Report
Sep 08, 2022
4
Insider Trading
Sep 06, 2022
4
Insider Trading

Latest Insider Trading transactions for IDXX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-14
MAZELSKY JONATHAN JAY
SOLD
-4,561,910
434.468
-10,500
President & CEO
2022-11-14
MAZELSKY JONATHAN JAY
ACQUIRED
1,177,880
62
18,998
President & CEO
2022-11-11
Turner Kathy V
ACQUIRED
1,527,150
178.26
8,567
Senior Vice President
2022-11-11
Turner Kathy V
SOLD
-3,756,920
438.534
-8,567
Senior Vice President
2022-11-10
Turner Kathy V
ACQUIRED
1,098,850
206.94
5,310
Senior Vice President
2022-11-10
Turner Kathy V
SOLD
-2,164,460
407.62
-5,310
Senior Vice President
2022-11-07
MAZELSKY JONATHAN JAY
ACQUIRED
1,248,100
52
24,002
President & CEO
2022-11-07
MAZELSKY JONATHAN JAY
SOLD
-5,060,320
382.488
-13,230
President & CEO
2022-10-28
JUNIUS DANIEL M
ACQUIRED
6,557.04
364.28
18
-
2022-09-06
AYERS JONATHAN W
GIFTED
-
-
450,000
-

1–10 of 50

Jonathan J. Mazelsky
10400
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenue$ 841,661$ 810,421$ 2,538,756$ 2,414,270
Cost of Revenue:    
Cost of revenue335,035337,5001,019,345981,259
Gross profit506,626472,9211,519,4111,433,011
Expenses:    
Sales and marketing130,021124,434392,570358,277
General and administrative83,76482,098243,201226,194
Research and development48,01340,427211,402115,703
Income from operations244,828225,962672,238732,837
Interest expense(10,998)(7,134)(26,311)(22,331)
Interest income353122830265
Income before provision for income taxes234,183218,950646,757710,771
Provision for income taxes53,24543,772139,875128,698
Net income180,938175,178506,882582,073
Less: Net loss attributable to noncontrolling interest0(57)0(1)
Net income attributable to IDEXX Laboratories, Inc. stockholders$ 180,938$ 175,235$ 506,882$ 582,074
Earnings per Share:    
Basic (in USD per share)$ 2.17$ 2.06$ 6.04$ 6.82
Diluted (in USD per share)$ 2.15$ 2.03$ 5.97$ 6.71
Weighted Average Shares Outstanding:    
Basic (in shares)83,24785,12383,85585,325
Diluted (in shares)84,11386,51184,85886,712
Product revenue    
Revenue:    
Total revenue$ 481,004$ 471,787$ 1,451,899$ 1,406,850
Cost of Revenue:    
Cost of revenue158,554166,748487,948483,850
Service revenue    
Revenue:    
Total revenue360,657338,6341,086,8571,007,420
Cost of Revenue:    
Cost of revenue$ 176,481$ 170,752$ 531,397$ 497,409

IDXX Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 99,176$ 144,454
Accounts receivable, net388,072368,348
Inventories354,975269,030
Other current assets216,636173,823
Total current assets1,058,859955,655
Long-Term Assets:  
Property and equipment, net612,405587,667
Operating lease right-of-use assets110,103105,101
Goodwill355,292359,345
Intangible assets, net99,96899,035
Other long-term assets403,440330,400
Total long-term assets1,581,2081,481,548
TOTAL ASSETS2,640,0672,437,203
Current Liabilities:  
Accounts payable110,144116,140
Accrued liabilities405,992458,909
Line of credit633,00073,500
Current portion of long-term debt074,996
Current portion of deferred revenue40,80940,034
Total current liabilities1,189,945763,579
Long-Term Liabilities:  
Deferred income tax liabilities14,4868,935
Long-term debt, net of current portion760,814775,205
Long-term deferred revenue, net of current portion34,74241,174
Long-term operating lease liabilities93,12887,377
Other long-term liabilities70,95370,941
Total long-term liabilities974,123983,632
Total liabilities2,164,0681,747,211
Commitments and Contingencies (Note 16)
Stockholders’ Equity:  
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 107,095 shares in 2022 and 106,878 shares in 2021; Outstanding: 82,995 shares in 2022 and 84,562 shares in 202110,70910,688
Additional paid-in capital1,437,5281,377,320
Deferred stock units: Outstanding: 58 units in 2022 and 90 units in 20215,1765,719
Retained earnings3,427,3222,920,440
Accumulated other comprehensive loss(80,894)(53,484)
Treasury stock, at cost: 24,101 shares in 2022 and 22,317 shares in 2021(4,323,842)(3,570,691)
Total stockholders’ equity475,999689,992
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 2,640,067$ 2,437,203